目的 探讨灯盏生脉胶囊联合尼可地尔片治疗冠心病心绞痛的临床疗效。方法 选取2020年1月—2021年3月平煤神马医疗集团总医院治疗的124例冠心病心绞痛患者为研究对象，按照随机数字方法分为对照组（62例）和治疗组（62例）。对照组患者口服尼可地尔片，5 mg/次，3次/d。治疗组患者在对照组基础上口服灯盏生脉胶囊，2粒/次，3次/d。两组患者均连续治疗14 d。观察对比两组患者的临床疗效、心电图疗效、心绞痛发作次数及持续时间。同时比较两组治疗前后SF-36量表评分、基质金属蛋白酶相关指标、炎性因子水平、氧化应激指标的变化情况。结果 治疗后，治疗组总有效率是95.16%，显著高于对照组的79.03%（P<0.05）。治疗后，治疗组心电图疗效总有效率是95.16%，显著高于对照组的80.65%（P<0.05）。治疗后，两组心绞痛发作次数及心绞痛持续时间均显著降低（P<0.05），且治疗后治疗组心绞痛发作情况改善优于对照组（P<0.05）。治疗后两组SF-36量表评分均升高（P<0.05）；治疗后治疗组SF-36量表评分高于对照组（P<0.05）。治疗后，两组患者白细胞介素-18（IL-18）、肿瘤坏死因子（TNF-α）、可溶性细胞间黏附分子（sICAM-1）均较治疗前显著降低（P<0.05）；治疗后，治疗组炎症因子水平低于对照组（P<0.05）。治疗后，两组超氧化物歧化酶（SOD）均较治疗前显著升高，但脂质过氧化物（LPO）、丙二醛（MDA）均降低（P<0.05）；治疗后，治疗组SOD水平较对照组升高，LPO、MDA水平较对照组降低（P<0.05）。治疗后，两组基质金属蛋白酶抑制因子1（TIMP-1）均有所升高，但基质金属蛋白酶-9（MMP-9）有所降低（P<0.05）；治疗后，治疗组TIMP-1水平高于对照组，但MMP-9水平低于对照组（P<0.05）。结论 灯盏生脉胶囊联合尼可地尔片治疗可以提高冠心病心绞痛患者临床疗效，有效改善患者心绞痛发作次数及心绞痛持续时间，提高日常生活质量，改善炎性反应、氧化应激反应，值得临床广泛应用。

Objective To investigate the clinical effect of Dengzhan Shengmai Capsules combined with nicorandil in treatment of coronary heart disease angina pectoris. Methods A total of 124 patients with coronary heart disease angina pectoris admitted to General Hospital of Pingmei Shenma Medical Group were selected as the research objects from January 2020 to March 2021, and divided into control group (62 cases) and treatment group (62 cases) according to the random number method. Patients in the control group were po administered with Nicorandil Tablets, 5 mg/time, three times daily. Patients in the treatment group were po administered with Dengzhan Shengmai Capsules on the basis of the control group, 2 grains/time, three times daily. Patients in two groups were treated for 14 d. After treatment, clinical efficacy, ECG efficacy, angina attack frequency and duration were observed and compared between the two groups. Meanwhile, SF-36 scale score, matrix metalloproteinase-related indexes, inflammatory factor levels and oxidative stress indexes of the two groups were compared before and after treatment. Results After treatment, the total effective rate of treatment group was 95.16%, significantly higher than 79.03% of control group (P<0.05). After treatment, the total effective rate of ECG in the treatment group was 95.16%, significantly higher than 80.65% in the control group (P<0.05). After treatment, the number of angina attacks and duration of angina pectoris in both groups were significantly decreased (P<0.05), and the improvement of angina pectoris attacks in the treatment group was better than that in the control group (P<0.05). After treatment, the SF-36 score in both groups increased (P<0.05). After treatment, the SF-36 score of the treatment group was higher than that of the control group (P<0.05). After treatment, IL-18, TNF-α, and sICAM-1 in two groups were significantly decreased before treatment (P<0.05). After treatment, the level of inflammatory factors in the treatment group was lower than that in the control group (P<0.05). After treatment, SOD in both groups was significantly increased compared with before treatment, but LPO and MDA were decreased (P<0.05). After treatment, SOD level in the treatment group was higher than that in the control group, while LPO and MDA levels were lower than that in the control group (P<0.05). After treatment, TIMP-1 was increased in both groups, but MMP9 was decreased (P<0.05). After treatment, TIMP-1 level in the treatment group was higher than that in the control group, but MMP9 level was lower than that in the control group (P<0.05). Conclusions Dengzhan Shengmai Capsules combined with Nicorandil Tablets can improve the clinical efficacy of patients with angina pectoris of coronary heart disease, and can effectively improve the frequency and duration of angina pectoris, improve the quality of daily life, and improve the inflammatory response and oxidative stress response, which is worthy of widespread clinical application.

R972